Report Detail
Global (United States, European Union and China) Schizophrenia Drugs Market Research Report 2019-2025
- RnM3635447 |
- 30 July, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Schizophrenia is a mental disorder characterized by abnormal social behavior and failure to understand reality. Common symptoms include false beliefs, unclear or confused thinking, hearing voices that others do not, reduced social engagement and emotional expression, and a lack of motivation.
In 2019, the market size of Schizophrenia Drugs is 5310 million US$ and it will reach 6470 million US$ in 2025, growing at a CAGR of 2.5% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Schizophrenia Drugs.
This report studies the global market size of Schizophrenia Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Schizophrenia Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Johnson & Johnson
Bristol-Myers Squibb
Otsuka Pharma
AstraZeneca
Sumitomo Dainippon
Eli Lilly
Alkermes
Vanda Pharma
Allergan
Pfizer
Market Segment by Product Type
Oral Antipsychotics
Injectable Antipsychotics
Market Segment by Application
Hospital
Clinic
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Schizophrenia Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Schizophrenia Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Schizophrenia Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Schizophrenia Drugs Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Oral Antipsychotics
- 1.3.3 Injectable Antipsychotics
- 1.4 Market Segment by Application
- 1.4.1 Global Schizophrenia Drugs Market Share by Application (2019-2025)
- 1.4.2 Hospital
- 1.4.3 Clinic
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Schizophrenia Drugs Market Size
- 2.1.1 Global Schizophrenia Drugs Revenue 2014-2025
- 2.1.2 Global Schizophrenia Drugs Sales 2014-2025
- 2.2 Schizophrenia Drugs Growth Rate by Regions
- 2.2.1 Global Schizophrenia Drugs Sales by Regions 2014-2019
- 2.2.2 Global Schizophrenia Drugs Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Schizophrenia Drugs Sales by Manufacturers
- 3.1.1 Schizophrenia Drugs Sales by Manufacturers 2014-2019
- 3.1.2 Schizophrenia Drugs Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Schizophrenia Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Schizophrenia Drugs Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Schizophrenia Drugs Market Concentration Ratio (CR5 and HHI)
- 3.3 Schizophrenia Drugs Price by Manufacturers
- 3.4 Key Manufacturers Schizophrenia Drugs Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Schizophrenia Drugs Market
- 3.6 Key Manufacturers Schizophrenia Drugs Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Oral Antipsychotics Sales and Revenue (2014-2019)
- 4.1.2 Injectable Antipsychotics Sales and Revenue (2014-2019)
- 4.2 Global Schizophrenia Drugs Sales Market Share by Type
- 4.3 Global Schizophrenia Drugs Revenue Market Share by Type
- 4.4 Schizophrenia Drugs Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Schizophrenia Drugs Sales by Application
6 United States
- 6.1 United States Schizophrenia Drugs Breakdown Data by Company
- 6.2 United States Schizophrenia Drugs Breakdown Data by Type
- 6.3 United States Schizophrenia Drugs Breakdown Data by Application
7 European Union
- 7.1 European Union Schizophrenia Drugs Breakdown Data by Company
- 7.2 European Union Schizophrenia Drugs Breakdown Data by Type
- 7.3 European Union Schizophrenia Drugs Breakdown Data by Application
8 China
- 8.1 China Schizophrenia Drugs Breakdown Data by Company
- 8.2 China Schizophrenia Drugs Breakdown Data by Type
- 8.3 China Schizophrenia Drugs Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Schizophrenia Drugs Breakdown Data by Company
- 9.2 Rest of World Schizophrenia Drugs Breakdown Data by Type
- 9.3 Rest of World Schizophrenia Drugs Breakdown Data by Application
- 9.4 Rest of World Schizophrenia Drugs Breakdown Data by Countries
- 9.4.1 Rest of World Schizophrenia Drugs Sales by Countries
- 9.4.2 Rest of World Schizophrenia Drugs Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Johnson & Johnson
- 10.1.1 Johnson & Johnson Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.1.4 Schizophrenia Drugs Product Introduction
- 10.1.5 Johnson & Johnson Recent Development
- 10.2 Bristol-Myers Squibb
- 10.2.1 Bristol-Myers Squibb Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.2.4 Schizophrenia Drugs Product Introduction
- 10.2.5 Bristol-Myers Squibb Recent Development
- 10.3 Otsuka Pharma
- 10.3.1 Otsuka Pharma Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.3.4 Schizophrenia Drugs Product Introduction
- 10.3.5 Otsuka Pharma Recent Development
- 10.4 AstraZeneca
- 10.4.1 AstraZeneca Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.4.4 Schizophrenia Drugs Product Introduction
- 10.4.5 AstraZeneca Recent Development
- 10.5 Sumitomo Dainippon
- 10.5.1 Sumitomo Dainippon Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.5.4 Schizophrenia Drugs Product Introduction
- 10.5.5 Sumitomo Dainippon Recent Development
- 10.6 Eli Lilly
- 10.6.1 Eli Lilly Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.6.4 Schizophrenia Drugs Product Introduction
- 10.6.5 Eli Lilly Recent Development
- 10.7 Alkermes
- 10.7.1 Alkermes Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.7.4 Schizophrenia Drugs Product Introduction
- 10.7.5 Alkermes Recent Development
- 10.8 Vanda Pharma
- 10.8.1 Vanda Pharma Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.8.4 Schizophrenia Drugs Product Introduction
- 10.8.5 Vanda Pharma Recent Development
- 10.9 Allergan
- 10.9.1 Allergan Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.9.4 Schizophrenia Drugs Product Introduction
- 10.9.5 Allergan Recent Development
- 10.10 Pfizer
- 10.10.1 Pfizer Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Schizophrenia Drugs
- 10.10.4 Schizophrenia Drugs Product Introduction
- 10.10.5 Pfizer Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Schizophrenia Drugs Sales Channels
- 11.2.2 Schizophrenia Drugs Distributors
- 11.3 Schizophrenia Drugs Customers
12 Market Forecast
- 12.1 Global Schizophrenia Drugs Sales and Revenue Forecast 2019-2025
- 12.2 Global Schizophrenia Drugs Sales Forecast by Type
- 12.3 Global Schizophrenia Drugs Sales Forecast by Application
- 12.4 Schizophrenia Drugs Forecast by Regions
- 12.4.1 Global Schizophrenia Drugs Sales Forecast by Regions 2019-2025
- 12.4.2 Global Schizophrenia Drugs Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Schizophrenia Drugs. Industry analysis & Market Report on Schizophrenia Drugs is a syndicated market report, published as Global (United States, European Union and China) Schizophrenia Drugs Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Schizophrenia Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
